Scan to discover online Background & Objective: Ovarian cancer is one of the most common cancers amongst women. The association of Human papillomavirus (HPV) and Epstein-Barr virus (EBV) with ovarian cancer is inconclusive; therefore, the aims of this study were to evaluate the frequency of HPV and EBV in malignant, borderline, benign and normal ovarian tissues. Methods: In this case-control study, 205 Paraffin-embedded ovarian tissue specimens including 68 malignant, 27 borderline, 65 benign, and 45 normal tissues were included from December 2014 to January 2018 and subjected to DNA extraction. The β-globin gene was amplified using PCR to confirm the quality of the extracted DNA. The genomes of HPV (genotypes 16 and 18) and EBV were identified, using specific primers by PCR. Results: The mean age of participants was 43.42 ± 15.4 years. The frequency of HPV was statistically significant between malignant versus benign (P=0.02) and control groups (P=0.002), but not with borderline tumor group (P=0.78). Amongst HPV infected samples, 1 (4.5%) and 14 (63.6%) samples were infected with types 16 and 18, respectively. Also 4 (18.2 %) samples were infected with both genotypes. Eleven samples including 7(10.3%) malignant, 1 (3.7%) borderline, 3 (4.6%) benign and none (0%) of normal control groups were infected with EBV, which was statistically different between malignant and the normal control group (P=0.03). Conclusion: The results of our study showed the possible role of high risk HPVs as well as EBV in pathogenesis of ovarian cancer, and further studies are recommended to confirm these findings.
Background: Co -infection of hepatitis E virus (HEV) and hepatitis D virus (HDV) in human immunodeficiency virus (HIV) infected patients can develop and increase hepatic complications in the world, particularly in developing countries. Objectives: The purpose of this study was to assess and compare the sero -virological prevalence of HEV and HDV in patients bearing HIV infection and HIV/HCV co -infection, as well as their relation to clinical and demographic data. Methods: Cross -sectional study testing IgM/IgG anti -HEV and total antibodies HDV in serum samples belong to 73 HIV infected patients and co -infected HIV -HCV patients were evaluated. Demographic, lifestyle, and laboratory data such as CD4 counts and viral load were prospectively collected on each patient with the HIV infection. Results: There were 26 HEV infected patients IgG positive, two HEV infected patients IgM positive, two HDV infected patients total antibodies positive, and only one HDV infected patient IgM among the 73 HIV infected patients. The prevalence of HDV positive IgG and total anti -HDV among co -infected patients were 2.2% and 2.2%. In addition 18 (69.2%) and 2.2% were positive for anti -HEV IgG and IgM, respectively. Furthermore, HIV viral load among HIV co -infected patients with HEV or HDV were shown higher compared to patients solely infected with only HIV. Also, the numbers of HEV or HDV positive were high in low levels of CD4. Conclusions: According to the results, frequency of occurrence of hepatitis E was higher than hepatitis D in HIV infected patients. Severity of HIV infection and liver damage caused by HEV and HDV infections were in a direct relationship. Hence, HIV and HCV screening should be implemented in HIV -infected patients with liver damage.
Background and Aim: Evidence linking the BK virus (BKV), John Cunningham virus (JCV), and Cytomegalovirus (CMV) to ovarian cancer is inconclusive. Therefore, this study aimed to evaluate the association of BKV, JCV, and CMV in malignant, borderline, benign, and normal ovarian tissues to shed light on the potential role of viral infections in the process of ovarian carcinogenesis. Materials and Methods:Paraffin-embedded ovarian tissues of 205 patients and 45 normal controls were included in this case-control study conducted from January 2015 to January 2020. The patient group was divided into three subgroups: malignant, borderline, and benign. Amplifying the β-globin gene was conducted to confirm the quality of the DNA extracted. Real-time PCR was used to identify BKV, JCV, and CMV genomes in all specimens. Results:The mean age of the patients and the control group was 44.0 ± 11.4 and 34.2 ± 12.1 years old, respectively. One, two, and three malignant lesions were positive for the presence of BKV, JCV, and CMV, respectively. These viruses were not detected in any borderline, benign, or control lesions. Conclusion:The results of this study indicated no association between CMV, BKV, and JCV with ovarian cancer. Therefore, major studies are recommended to confirm these findings.
Background and Aims: Co-infection of hepatitis E virus (HEV) in chronic hepatitis C virus (HCV) infected patients can develop and cause an increase in liver disease and hepatic complications in the world. The purpose of this study was to assess the prevalence of HEV infection in patients suffering from chronic HCV infection. Materials and Methods: Cross-sectional study testing anti-HEV antibodies in serum samples belonged to 53 chronic HCV infected patients were evaluated. Demographic and clinical data such as liver function tests and enzymes level were prospectively collected on each patient with chronic HCV infection. Results: There were 5 HEV infected patients IgG positive among the 53 chronic HCV infected patients. These patients had an alanine aminotransferase (ALT) level twice the upper level about of the 48 HEV negative patients (p<0.0001). Conclusions: Prevalence of HEV sero-positivity patients with HCV co-infection patients was 9.4%. Our results suggest that HEV screening should be implemented in HCV-infected patients with cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.